Use access key #2 to skip to page content.
$1.55 -0.20 (-11.43%)
10/10/2008 3:59 PM

Achillion Pharmaceuticals, Inc. (ACHN)

CAPS Rating:
No stars

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

ACHN doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

16 Outperforms
3 Underperforms
 

All-Stars

8 Outperforms
2 Underperforms
 

Wall Street

2 Outperforms
0 Underperforms
 

Members bullish on ACHN are also bullish on:

Members bearish on ACHN are also bearish on:

Ticker Tags

Bio-Pharmaceuticals (26), Biotechnology (295), IPO in 2006 (165), Micro Cap (4824)
Suggest a tag

Achillion Pharmaceuticals, Inc. At A Glance

Current Price: $1.55
Last Trade Time: 10/10/2008 3:59 PM
Open: $1.69
Previous Close: $1.75
Daily Range: $1.50 - $2.00
52-Week Range: $0.85 - $6.75
Volume: 27,190
Market Cap: $46.16M
P/E Ratio: 0.21
Compare Our Special Broker Offers!

Stock Trends

ACHN VS S&P 500 (SPY)

ACHN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ACHN

More Headlines...

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 2 of 2  

Recs

0

 (ACHN)

Avatar NetscribePhrmtcl (96.34) Submitted: 3/20/07 8:42 AM : Underperform Start Price: $7.06 ACHN Score: 38.73

Achillion is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, the company concentrates on the development of antivirals and antibacterials. It is targeting the antiviral development efforts on treatments for HIV infection and chronic hepatitis C, and is directing its antibacterial development efforts toward treatments for serious hospital-based bacterial infections.


Its two lead drug candidates are Elvucitabine, which is in the Phase II clinical trials in HIV-infected patients, and ACH-806, which the company is evaluating in collaboration with Gilead Sciences in a Phase I clinical trial for the treatment of chronic hepatitis C. The company is also evaluating its third drug candidate, ACH-702, in late-stage, pre-clinical studies for the treatment of serious hospital-based bacterial infections.


Revenues witnessed a sharp 91% decline for the quarter ended September 2006. The decrease in 2006 is the result of a reduction in milestone payments under collaboration with Gilead Sciences. Net loss applicable to common shareholders increased 71%, reflecting a sharp increase in R&D expenses and administrative costs. The company has incurred losses of $100 million from inception to September 2006 and had an accumulated deficit of $113.6 million through September 30, 2006.


Achillion appears to be a weak investment proposition based on the delay in the expected development timeline for the HIV & HCV program. The launch of a replicase inhibitor for HCV is expected to be in 2011, rather than 2010, which would hamper the company’s near term earning prospects.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACHN)

Avatar turingmouse (98.95) Submitted: 2/12/07 2:05 AM : Outperform Start Price: $9.22 ACHN Score: -44.67

took to much of a beating on hep-c trial news. should outperform.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 2 of 2  

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCowenandCo 84.26 12/07/06 Outperform NS $17.25-91.01%-37.75%-53.26
TrackJMP 24.52 12/06/06 Outperform NS $16.76-90.75%-37.39%-53.36

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners